share_log

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Zoghbi Huda Y

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Zoghbi Huda Y

再生元製藥公司 | 4：持股變動聲明-董事 Zoghbi Huda Y
美股SEC公告 ·  01/06 16:14

Moomoo AI 已提取核心訊息

On January 2, 2025, Huda Y Zoghbi, a director at Regeneron Pharmaceuticals, was granted 166 shares of common stock at $0 per share. This transaction was reported as a direct acquisition, increasing Zoghbi's total beneficial ownership to 1,548 shares.The shares were acquired through a grant, award, or other acquisition program, as indicated by the transaction code 'A'. This type of transaction typically represents compensation or incentive awards for company executives and board members.The acquisition of these shares at no cost suggests they may be part of a restricted stock unit (RSU) grant or similar equity-based compensation plan. Such grants are common in the biotech and pharmaceutical industries to align the interests of key personnel with those of shareholders.
On January 2, 2025, Huda Y Zoghbi, a director at Regeneron Pharmaceuticals, was granted 166 shares of common stock at $0 per share. This transaction was reported as a direct acquisition, increasing Zoghbi's total beneficial ownership to 1,548 shares.The shares were acquired through a grant, award, or other acquisition program, as indicated by the transaction code 'A'. This type of transaction typically represents compensation or incentive awards for company executives and board members.The acquisition of these shares at no cost suggests they may be part of a restricted stock unit (RSU) grant or similar equity-based compensation plan. Such grants are common in the biotech and pharmaceutical industries to align the interests of key personnel with those of shareholders.
在2025年1月2日，來自再生元製藥公司的董事Huda Y Zoghbi獲得了166股每股價格爲$0的普通股。這筆交易被報告爲直接收購，增加了Zoghbi的總受益持股數至1,548股。這些股份是通過授予、獎勵或其他獲取計劃獲得的，交易編碼爲'A'。此類交易通常代表公司高管和董事會成員的薪酬或激勵獎勵。以零成本獲取這些股份表明它們可能是限制性股票單位（RSU）授予或類似的基於股權的薪酬計劃的一部分。這種授予在生物技術和藥品行業中很常見，旨在將關鍵人員的利益與股東的利益保持一致。
在2025年1月2日，來自再生元製藥公司的董事Huda Y Zoghbi獲得了166股每股價格爲$0的普通股。這筆交易被報告爲直接收購，增加了Zoghbi的總受益持股數至1,548股。這些股份是通過授予、獎勵或其他獲取計劃獲得的，交易編碼爲'A'。此類交易通常代表公司高管和董事會成員的薪酬或激勵獎勵。以零成本獲取這些股份表明它們可能是限制性股票單位（RSU）授予或類似的基於股權的薪酬計劃的一部分。這種授予在生物技術和藥品行業中很常見，旨在將關鍵人員的利益與股東的利益保持一致。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Nutriband
    NTRB
    -- 7.340
    Eterna Therapeutics
    ERNA
    -- 0.635
    Tonix Pharmaceuticals
    TNXP
    -- 0.3190
    ImmunoPrecise Antibodies
    IPA
    -- 0.645
    Sonnet BioTherapeutic
    SONN
    -- 2.0000
    解鎖完整榜單
    熱門中概股
    追蹤最熱門的中概股實時資訊。
    熱門討論
    12月CPI數據助推降息預期，美股能否延續強勢？
    美國12月CPI同比上漲2.9%，符合預期，但已連續三個月呈現上漲趨勢。市場對此反應積極，因為剔除食品和能源價格的核心CPI上漲了3.2%，是自2021年以來的最低讀數之一。12月PPI增長3.3%，低於預期的3.5%。美聯儲目標在2025年實現2.5%的通脹率，但密歇根調查數據 展开
    這是十二月CPI的分析，以一張圖表呈現